The Dark Art of Racecraft
By Ta-Nehisi Coates,
The Atlantic
| 05. 13. 2013
Dave Weigel is one of my favorite reporters, but I think
this piece on Jason Richwine, intelligence research, and "race" deserves a closer look:
Academics aren't so concerned with the politics. But they know all too well the risks that come with research connecting IQ and race. At the start of his dissertation, Richwine thanked his three advisers -- George Borjas, Christopher Jenks, and Richard Zeckhauser -- for being so helpful and so bold. Borjas "helped me navigate the minefield of early graduate school," he wrote. "Richard Zeckhauser, never someone to shy away from controversial ideas, immediately embraced my work. ..."
Anyone who works in Washington and wants to explore the dark arts of race and IQ research is in the right place. The city's a bit like a college campus, where investigating "taboo" topics is rewarded, especially on the right. A liberal squeals "racism," and they hear the political-correctness cops (most often, the Southern Poverty Law Center) reporting a thought crime.
It is almost as though the "dark arts of race and IQ" were an untapped field of potential...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...